Tosk

Tosk is a clinical-stage biotechnology company developing a novel class of small molecule adjunctive therapies designed to mitigate the severe, dose-limiting side effects of standard cancer treatments. Its lead candidate, TK-90, has completed proof-of-concept studies for preventing chemotherapy-induced mucositis, while other pipeline programs target cardiotoxicity, nephrotoxicity, and oncogenic KRAS. Leveraging a unique discovery platform and led by an experienced management team, Tosk seeks to address a significant unmet need in supportive oncology care with cost-effective, orally available drugs.

Proprietary drug discovery methods including a Genetically Modified Fly (Drosophila) platform for high-throughput, in-vivo screening of compounds to block drug side effects or inhibit cancer gene activity.

In supportive care, Tosk competes with other companies developing mucositis and chemoprotectant drugs, though its mechanism may be differentiated. In direct oncology, the KRAS space is intensely competitive, dominated by large pharma (Amgen, Mirati, etc.) with approved drugs and robust pipelines, requiring Tosk to demonstrate a best-in-class or broadly applicable profile to succeed.